BerGenBio

Selective AXL inhibitors

Home  /  2020  /  Page 5

Year: 2020

2021202020192018201720162015

BERGENBIO MEETS EFFICACY ENDPOINT for FIRST STAGE OF PHASE II TRIAL WITH AXL INHIBITOR BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN NSCLC PATIENTS PROGRESSING ON IMMUNE CHECKPOINT INHIBITORS

January 15, 2020

First stage clinical efficacy endpoint met for the Phase II trial cohort evaluating selective AXL…

Read More

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.